Barclays upgrade Ionis Pharmaceuticals (Ions) stock is Pt


IO Pharmaceuticals, Inc. (NASDAQ:ion) is one of 11 intermediate cap healthcare stocks to buy according to hedge funds. Barclays upgraded from “equal weight” to “overweight” with a price target of $51 ahead of its $57 price target, the Tryngolza Phase 3 Core/Core2 data. Flies. The company expects a trial to have a greater than 90% chance of colliding with the primary endpoint, and expects it to be likely to hit all important second biomarker endpoints.

Barclays upgrade Ionis Pharmaceuticals (Ions) stock is Pt
Barclays upgrade Ionis Pharmaceuticals (Ions) stock is Pt

A lab scientist who makes groundbreaking discoveries in biotechnology.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) has announced that its partner Biogen will share positive top-line results from a Phase 1 study of Saranelsen (ION306/BIIB115), an investigative antisense oligonucleotide (ASO) being developed for the potential treatment of spinal myophytic myobiology (SMA). While exploiting the same mechanism of action as Spinraza® (Nusinersen), but designed to achieve greater efficacy, Salanersen can achieve higher efficacy and allow for once a year. In the first quarter of 2025, Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) revenues increased 10% compared to the same period last year.

Although we acknowledge the potential of Aeon as an investment, we believe certain AI stocks offer a greater reverse chance, pose a risk of decline. If you’re looking for a highly undervalued AI stock that can make a significant profit from the tariff and supervision trends of the Trump era, check out our free report. Best Short-Term AI Stocks.

Read next: Analysts say they buy 13 cheap AI stocks and 11 unstoppable growth stocks are currently investing

Disclosure: None. This article was originally published Insider Monkey.

Leave a Reply

Your email address will not be published. Required fields are marked *